...
机译:威尼替腊西和血清抑制在慢性淋巴细胞白血病
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
F Hoffmann La Roche Ltd Welwyn Garden City Herts England;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
F Hoffmann La Roche Ltd Welwyn Garden City Herts England;
Univ Calif San Diego Moores Canc Ctr San Diego CA 92103 USA;
Wellington Blood &
Canc Ctr Capital &
Coast Dist Hlth Board Wellington New Zealand;
Queen Elizabeth 2 Hlth Sci Ctr Halifax NS Canada;
Univ Hosp Ludwig Maximilians Univ Munich Dept Internal Med 3 Munich Germany;
Monash Univ Monash Hematol Clayton Vic Australia;
Tom Baker Canc Clin Dept Hematol Calgary AB Canada;
Hosp Ramon &
Cajal Madrid Spain;
F Hoffmann La Roche Ltd Welwyn Garden City Herts England;
AbbVie Inc N Chicago IL USA;
Univ Ulm Dept Internal Med 3 Ulm Germany;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
Univ Ulm Dept Internal Med 3 Ulm Germany;
Erasmus MC Dept Immunol Lab Med Immunol Rotterdam Netherlands;
Erasmus MC Dept Immunol Lab Med Immunol Rotterdam Netherlands;
Univ Hosp Schleswig Holstein Dept Med 2 Campus Kiel Kiel Germany;
Univ Hosp Schleswig Holstein Dept Med 2 Campus Kiel Kiel Germany;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
Genentech Inc San Francisco CA USA;
Univ Hosp Cologne Dept Internal Med 1 Ctr Integrated Oncol Cologne Bonn Kerpener Str 62 D-50937;
机译:venetoclax加上血清型患者复合核型和慢性淋巴细胞白血病患者的高疗效
机译:在以前未经处理的慢性淋巴细胞白血病(CLL)患者中,用12个月固定venetoclax的持续时间固定为venetoclax plus obinutuzumab
机译:威尼索克克斯和ObInutuzumab对慢性淋巴细胞白血病的前线治疗
机译:使用机器学习生存率和分类方法预测慢性淋巴细胞白血病首次治疗的时间
机译:绝经后妇女慢性淋巴细胞白血病和小淋巴细胞淋巴瘤发生率的危险因素:妇女健康倡议(WHI)研究
机译:完全消除了慢性淋巴细胞白血病具有不寻常的皮肤参与高有丝分裂指数在时间限制后的venetoclax / ObInutuzumab治疗后
机译:12个月固定治疗持续时间venetoclax与Obinutuzumab在此前未经处理过的慢性淋巴细胞白血病患者中的预算影响